PASS Assisted Prediction and Meta-analysis of Active Phytoconstituents of Guggul for the Treatment of Chronic Prostatitis: A Gateway to Cure Prostate Cancer

Jump To References Section

Authors

  • Vinayak Bhushan
     School of Pharmacy, Sharda University, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh – 201310, India ,IN
  • Rakesh K. Sindhu
     School of Pharmacy, Sharda University, Gr Noida ,IN

DOI:

https://doi.org/10.18311/jnr/2024/43424

Keywords:

Inflammation, Guggul, Meta-analysis, PASS, Prostate Cancer, Prostatitis

Abstract

Background: Mostly men are particularly prone to prostate cancer as well as chronic prostatitis the underlying causes behind prostate cancer as well as chronic prostatitis are multifaceted as well as diverse a spike in serum prostate-specific antigen characterises both diseases. Chronic prostatitis is prostate inflammation independent of the source inflammation and is linked to a variety of malignancies in general along with prostate inflammatory reactions that are thought to have a contributing influence on the advancement and growth of prostate cancer. Aim: This study aims to identify different phytoconstituents of Guggulu for treating chronic prostatitis along with meta-analysis. Meta-analysis is used as an analytical technique to aggregate results of separate inferential statistics investigations of clinical data on chronic prostatitis. Methods: Phytochemical ingredients were analyzed using PASS estimates. Canonical SMILES were identified to determine Pa values. PASS software was then used to forecast activities. Doxycycline, a conventional drug for chronic prostatitis, was selected for comparison. Data was collected using the PASS online program to estimate physiological and biochemical parameters. The activities of all constituents were then compared against doxycycline. Results: The results indicate that Guggul sterone Z shows promise as a candidate for further investigation in medication therapy for chronic prostatitis. A meta-analysis aims to identify clinical trials for this phytoconstituent, which has yielded the highest number of results. PASS prediction findings reveal that Guggul sterone Z, followed by Mansumbinone, 16-dehydroprogesterone, and alpha-pinene, exhibit the most significant activities. Conclusion: The study forecasted that Guggul sterone Z, Mansumbinone, 16-dehydroprogesterone and alpha-pinene are the potential phytoconstituents that can play a vital role in the development of novel treatments for chronic prostatitis-induced prostate cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2024-10-07

How to Cite

Bhushan, V., & Sindhu, R. K. (2024). PASS Assisted Prediction and Meta-analysis of Active Phytoconstituents of <i>Guggul</i> for the Treatment of Chronic Prostatitis: A Gateway to Cure Prostate Cancer. Journal of Natural Remedies, 24(9), 1987–2003. https://doi.org/10.18311/jnr/2024/43424

Issue

Volume 24, Issue 9, September 2024

Section

Research Articles

Categories

License

Copyright (c) 2024 Vinayak Bhushan, Rakesh K Sindhu (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2024-03-31
Accepted 2024-07-30
Published 2024-10-07

 

References

Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C. The role of prostatitis in prostate cancer: meta-analysis. PLoS One. 2013; 8(12). https://doi.org/10.1371/journal.pone.0085179 PMid:24391995 PMCid: PMC3877315

Bhushan V, Sindhu RK. In silico evaluation of bioactive compounds from natural sources targeting NIK and NFκB pathways for chronic prostatitis therapy and ADMET profile analysis. Educational Administration: Theory and Practice. 2024; 30(3):2381–2388. https://doi.org/10.53555/ kuey.v30i3.5188

Sui X, Lei L, Chen L, Xie T, Li X. Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget. 2017; 8(54):93279-94. https:// doi.org/10.18632/oncotarget.21565 PMid:29190997 PMCid: PMC5696263

de Godoy Fernandes G, Pedrina B, de Faria Lainetti P, et al. Morphological and molecular characterization of proliferative inflammatory atrophy in canine prostatic samples. Cancers (Basel). 2021; 13(8):1887. https://doi.org/10.3390/cancers13081887 PMid:33920045 PMCid: PMC8071022

Roehrborn CG. Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). Med Clin North Am. 2011; 95(1):87-100. https://doi.org/10.1016/j.mcna.2010.08.013 PMid:21095413

Yamada T, Sugimoto K. Guggul sterone and its role in chronic diseases. Adv Exp Med Biol. 2016; 929:329-61. https://doi.org/10.1007/978-3-319-41342-6_15 PMid:27771932

Garang Z, Feng Q, Luo R, et al. Commiphora mukul (Hook. ex-Stocks) Engl.: Historical records, application rules, phytochemistry, pharmacology, clinical research, and adverse reactions. J Ethnopharmacol. 2023; 317:116717.https://doi.org/10.1016/j.jep.2023.116717 PMid:37301302

Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggul sterone inhibits tumour cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol. 2007; 74(1):118-30. https://doi.org/10.1016/j.bcp.2007.03.026 PMid:17475222 PMCid: PMC2744036

Shah R, Gulati V, Palombo EA. Pharmacological properties of Guggul sterone, the major active component of gum Guggul. Phytother Res. 2012; 26(11):1594-605. https://doi.org/10.1002/ptr.4647 PMid:22388973

Kumar R, Kumar R, Anand A, Sharma N, Khurana N. Prediction of antiparkinson potential of phytoconstituents using prediction of activity spectra of substances software. Asian J Pharm Clin Res. 2018; 11(14):48. https://doi.org/10.22159/ajpcr.2018.v11s2.28578

Hedges LV. Meta-analysis. J Educ Stat. 1992; 17(4):279-96. https://doi.org/10.3102/10769986017004279

Forero DA, Lopez-Leon S, González-Giraldo Y, Bagos PG. Ten simple rules for carrying out and writing metaanalyses. PLoS Comput Biol. 2019; 15(5). https://doi.org/10.1371/journal.pcbi.1006922 PMid:31095553 PMCid: PMC6521986

Shishodia S, Aggarwal BB. Guggul sterone inhibits NFkappaB and IkappaBalpha kinase activation, suppresses the expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem. 2004; 279(45):47148-58. https://doi.org/10.1074/jbc.M408093200 PMid:15322087

da Costa BR, Rutjes AW, Johnston BC, et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: metaepidemiological study. Int J Epidemiol. 2012; 41(5):144559. https://doi.org/10.1093/ije/dys124 PMid:23045205

Shishodia S, Harikumar KB, Dass S, Ramawat KG, Aggarwal BB. The Guggulu for chronic diseases: ancient medicine, modern targets. Anticancer Res. 2008; 28(6A):3647-64.

Roy NK, Deka A, Bordoloi D, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett. 2016; 377(1):74-86. https://doi.org/10.1016/j.canlet.2016.04.017 PMid:27091399

Haidich AB. Meta-analysis in medical research. Hippokratia. 2010; 14(Suppl 1):29-37.

Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. Urology. 2006; 67(1):60-3. https://doi.org/10.1016/j.urology.2005.07.035 PMid:16413333

Lombardo F, Fiducia M, Lunghi R, et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia. 2012; 44(Suppl 1):672-8. https://doi.org/10.1111/j.14390272.2011.01248.x PMid:22053857

Banothe, Gajiram Dharamdas et al. A clinical evaluation of Kanchanara Guggulu and Bala Taila Matra Basti in the management of Mutraghata with special reference to benign prostatic hyperplasia. Ayu. 2018; 39(2):65-71. https://doi.org/10.4103/ayu.AYU_117_15

Javed D, Kumar P, Shukla D, et al. A clinical study to evaluate the effect of "Kanchanara Guggulu and Vir-Tarvadi Gana Kashaya" in the management of Benign Prostate Hyperplasia (BPH). Unique J Ayurvedic Herbal Med. 2015; (01):3.

Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999; 54(6):960-3. https://doi.org/10.1016/S00904295(99)00358-1 PMid:10604689

Maurizi A, De Luca F, Zanghi A, et al. The role of nutraceutical medications in men with nonbacterial chronic prostatitis and chronic pelvic pain syndrome: a prospective nonblinded study utilizing flower pollen extracts versus bioflavonoids. Arch Ital Urol Androl. 2019; 90(4):260-4. https://doi.org/10.4081/aiua.2018.4.260 PMid:30655636

Patel JK, Dudhamal T. A standard controlled clinical study of Varuna Shigru Guggulu and Bala Taila Matra Basti in the management of Mootraghata (benign prostatic hyperplasia). J Res Ayurvedic Sci. 2018; 2(3):164. https://doi.org/10.5005/jp-journals-10064-0053

Joyal P, S DT, K GS, D MV. Management of Mootraghata (benign prostatic hyperplasia) with herbal remedies: a pilot study. Int J Ayurvedic Med. 2014; 5(1).

De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155(6):1985-92. https://doi.org/10.1016/S00029440(10)65517-4 PMid:10595928

Langston ME, Horn M, Khan S, et al. A systematic review and meta-analysis of associations between clinical prostatitis and prostate cancer: new estimates accounting for detection bias. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1594-603. https://doi.org/10.1158/1055-9965. EPI-19-0387 PMid:31337640 PMCid: PMC6774844

Krušlin B, Tomas D, Džombeta T, Milković-Periša M, Ulamec M. Inflammation in prostatic hyperplasia and carcinoma: basic scientific approach. Front Oncol. 2017; 7:77. https://doi.org/10.3389/fonc.2017.00077 PMid:28487844 PMCid: PMC5403898

Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancerrelated inflammation. Biochem Med (Zagreb). 2011; 21(3):264-75. https://doi.org/10.11613/BM.2011.036 PMid:22420240

Malhab LJB, Saber-Ayad MM, Al-Hakm R, et al. Chronic inflammation and cancer: the role of endothelial dysfunction and vascular inflammation. Curr Pharm Des. 2021; 27(18):2156-69. https://doi.org/10.2174/1381612827 666210303143442 PMid:33655853

Singh SV, Choi S, Zeng Y, Hahm ER, Xiao D. Guggul sterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res. 2007; 67(15):7439-49. https://doi.org/10.1158/0008-5472.CAN-07-0120 PMid:17671214

Shrivastava A, Gupta VB. Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health. 2012; 3(1):10-9. https://doi.org/10.4103/0976-7800.98811 PMid:22923974 PMCid: PMC3425142

Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, et al. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers (Basel). 2023; 15(12):3110. https://doi.org/10.3390/cancers15123110 PMid:37370720 PMCid: PMC10296711

Kim S, Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023; 51(D1). https://doi.org/10.1093/nar/gkac956 PMid:36305812 PMCid: PMC9825602